Drug news
CHMP recommends Eviplera triple therapy for HIV-1 infection
The CHMP has adopted a positive opinion for the once-daily single-tablet regimen, Eviplera, combining Gilead's Truvada (emtricitabine and tenofovir disoproxil (as fumarate)) with Tibotec Pharmaceuticals' non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine (as hydrochloride)) from Gilead, for the treatment of HIV-1 infection in antiretroviral-naive adults with a viral load less than or equal to 100,000 HIV-1 RNA copies. The combination is approved in the USA as Complera.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins